Krystal Biotech (KRYS) Expected to Announce Earnings on Wednesday

Krystal Biotech (NASDAQ:KRYS - Get Free Report) is anticipated to announce its Q4 2024 earnings results before the market opens on Wednesday, February 19th. Analysts expect the company to announce earnings of $1.29 per share and revenue of $91.35 million for the quarter. Investors that wish to register for the company's conference call can do so using this link.

Krystal Biotech (NASDAQ:KRYS - Get Free Report) last released its quarterly earnings data on Wednesday, February 19th. The company reported $1.52 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.29 by $0.23. The business had revenue of $91.10 million for the quarter, compared to analysts' expectations of $91.35 million. Krystal Biotech had a return on equity of 7.54% and a net margin of 21.68%. Krystal Biotech's quarterly revenue was up 116.4% on a year-over-year basis. During the same period in the previous year, the business posted $0.30 earnings per share. On average, analysts expect Krystal Biotech to post $3 EPS for the current fiscal year and $6 EPS for the next fiscal year.

Krystal Biotech Price Performance

Shares of KRYS traded up $19.48 on Wednesday, reaching $176.17. 650,045 shares of the stock traded hands, compared to its average volume of 250,604. The firm has a market cap of $5.07 billion, a price-to-earnings ratio of 99.53 and a beta of 0.84. Krystal Biotech has a 12 month low of $107.50 and a 12 month high of $219.34. The stock's 50-day moving average price is $157.40 and its 200-day moving average price is $175.17.

Wall Street Analyst Weigh In

Several analysts recently commented on KRYS shares. Citigroup boosted their price target on Krystal Biotech from $204.00 to $206.00 and gave the company a "neutral" rating in a research note on Tuesday, November 5th. Chardan Capital reaffirmed a "buy" rating and issued a $212.00 price target on shares of Krystal Biotech in a research note on Wednesday, December 18th. Finally, HC Wainwright reaffirmed a "buy" rating and issued a $221.00 price target on shares of Krystal Biotech in a research note on Wednesday. One equities research analyst has rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat, Krystal Biotech currently has a consensus rating of "Buy" and a consensus target price of $206.67.

Insiders Place Their Bets

In other Krystal Biotech news, insider Suma Krishnan sold 25,000 shares of the business's stock in a transaction on Friday, December 13th. The stock was sold at an average price of $164.78, for a total value of $4,119,500.00. Following the transaction, the insider now owns 1,475,882 shares of the company's stock, valued at approximately $243,195,835.96. The trade was a 1.67 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 14.10% of the company's stock.

Krystal Biotech Company Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).